Dicerna to pay $27M to settle Alnylam trade secrets lawsuit
April 20, 2018 at 14:20 PM EDT
The Cambridge biotechs are both developing RNA interference drugs, which are designed to silence disease-causing genes.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|